Full text is available at the source.
Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist
Creating new compounds that activate the PPARγ protein without using TZD chemicals
AI simplified
Abstract
Non-TZD PPARγ agonists may produce effects similar to thiazolidinediones without adverse effects.
- Thiazolidinediones (TZDs) improve insulin sensitivity in type 2 diabetes by targeting the PPARγ receptor.
- TZDs enhance fatty acid production and glucose metabolism, increasing insulin sensitivity in key tissues.
- Adverse effects of TZDs include weight gain and liver toxicity.
- Non-TZD PPARγ agonists have been identified which could replicate the beneficial effects of TZDs.
- These non-TZD agonists may avoid the negative side effects associated with TZDs in animal models.
AI simplified